SignPath Pharma (United States)

Signpath Pharma is a clinical stage company that has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy. Its first clinical application is LipoCurc™, a proprietary liposomal formulation of curcumin administered intravenously, which has completed Phase 1a and 1b clinical trials in 70 human subjects. A Phase 2 trial in first line treatment of glioblastoma is underway.

Signpath Pharma is a clinical stage company. It has developed the CorreQT platform technology to mitigate cardiac side effects of other drugs. Its first clinical application is LipoCurc™, a proprietary liposomal formulation of curcumin administered intravenously. LipoCurc™ has completed Phase 1a and 1b clinical trials in 70 human subjects. A Phase 2 trial in first line treatment of glioblastoma is underway.

• LipoCurc™

  A proprietary liposomal formulation of curcumin administered intravenously, with active and sustained levels of curcumin over 1000 times greater than traditional oral curcumin dosing, without cardiotoxicity.

• CorreQT platform

  A platform technology that mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.

1. 1Home - Signpath Pharmasignpathpharma.com
2. 2About Us - Signpath Pharmasignpathpharma.com
3. 3Prevention of Cardiac Side Effects - Signpath Pharmasignpathpharma.com
4. 4Liposomal Curcumin for Treatment of Cancer - Signpath Pharmasignpathpharma.com
5. 5SignPath Pharma (United States)wikidata.org